PortalPublikationenCoxsackie adenovirus receptor expression in carcinomas of th...

Coxsackie adenovirus receptor expression in carcinomas of the head and neck

Standard

Coxsackie adenovirus receptor expression in carcinomas of the head and neck. / Wunder, Tina; Schumacher, Udo; Friedrich, Reinhard E.

in: ANTICANCER RES, Jahrgang 32, Nr. 3, 01.03.2012, S. 1057-62.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wunder, T, Schumacher, U & Friedrich, RE 2012, 'Coxsackie adenovirus receptor expression in carcinomas of the head and neck', ANTICANCER RES, Jg. 32, Nr. 3, S. 1057-62.

APA

Wunder, T., Schumacher, U., & Friedrich, R. E. (2012). Coxsackie adenovirus receptor expression in carcinomas of the head and neck. ANTICANCER RES, 32(3), 1057-62.

Vancouver

Wunder T, Schumacher U, Friedrich RE. Coxsackie adenovirus receptor expression in carcinomas of the head and neck. ANTICANCER RES. 2012 Mär 1;32(3):1057-62.

Bibtex

@article{0702453ae113498998556faf6372c6ac,
title = "Coxsackie adenovirus receptor expression in carcinomas of the head and neck",
abstract = "BACKGROUND: Advanced stage head and neck squamous cell carcinomas (HNSCC) have a poor prognosis, this being particularly true for undifferentiated carcinomas. Adenoviral oncolytic therapy, whose success depends on the expression of the coxsackie adenovirus receptor (CAR) on tumour cells, might be an interesting therapeutic option. Thus CAR expression in HNSCC was evaluated in the current study.PATIENTS AND METHODS: CAR expression in 41 cases of HNSCC was investigated immunohistochemically.RESULTS: CAR expression was very heterogeneous and was more abundant in well differentiated carcinomas than in less differentiated ones. Expression decreased from 72.4% in G1 tumours to 56% in G4 tumours.CONCLUSION: As CAR expression decreases during malignant progression in HNSCC, its down-regulation in advanced grades of HNSCC is potential indicator of tumour progression. With regard to oncolytic therapy, CAR expression analysis should be performed prior to adenoviral oncolytic treatment to stratify patients for treatment.",
keywords = "Adult, Aged, Coxsackie and Adenovirus Receptor-Like Membrane Protein, Female, Head and Neck Neoplasms, Humans, Immunohistochemistry, Male, Middle Aged, Receptors, Virus",
author = "Tina Wunder and Udo Schumacher and Friedrich, {Reinhard E}",
year = "2012",
month = mar,
day = "1",
language = "English",
volume = "32",
pages = "1057--62",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

RIS

TY - JOUR

T1 - Coxsackie adenovirus receptor expression in carcinomas of the head and neck

AU - Wunder, Tina

AU - Schumacher, Udo

AU - Friedrich, Reinhard E

PY - 2012/3/1

Y1 - 2012/3/1

N2 - BACKGROUND: Advanced stage head and neck squamous cell carcinomas (HNSCC) have a poor prognosis, this being particularly true for undifferentiated carcinomas. Adenoviral oncolytic therapy, whose success depends on the expression of the coxsackie adenovirus receptor (CAR) on tumour cells, might be an interesting therapeutic option. Thus CAR expression in HNSCC was evaluated in the current study.PATIENTS AND METHODS: CAR expression in 41 cases of HNSCC was investigated immunohistochemically.RESULTS: CAR expression was very heterogeneous and was more abundant in well differentiated carcinomas than in less differentiated ones. Expression decreased from 72.4% in G1 tumours to 56% in G4 tumours.CONCLUSION: As CAR expression decreases during malignant progression in HNSCC, its down-regulation in advanced grades of HNSCC is potential indicator of tumour progression. With regard to oncolytic therapy, CAR expression analysis should be performed prior to adenoviral oncolytic treatment to stratify patients for treatment.

AB - BACKGROUND: Advanced stage head and neck squamous cell carcinomas (HNSCC) have a poor prognosis, this being particularly true for undifferentiated carcinomas. Adenoviral oncolytic therapy, whose success depends on the expression of the coxsackie adenovirus receptor (CAR) on tumour cells, might be an interesting therapeutic option. Thus CAR expression in HNSCC was evaluated in the current study.PATIENTS AND METHODS: CAR expression in 41 cases of HNSCC was investigated immunohistochemically.RESULTS: CAR expression was very heterogeneous and was more abundant in well differentiated carcinomas than in less differentiated ones. Expression decreased from 72.4% in G1 tumours to 56% in G4 tumours.CONCLUSION: As CAR expression decreases during malignant progression in HNSCC, its down-regulation in advanced grades of HNSCC is potential indicator of tumour progression. With regard to oncolytic therapy, CAR expression analysis should be performed prior to adenoviral oncolytic treatment to stratify patients for treatment.

KW - Adult

KW - Aged

KW - Coxsackie and Adenovirus Receptor-Like Membrane Protein

KW - Female

KW - Head and Neck Neoplasms

KW - Humans

KW - Immunohistochemistry

KW - Male

KW - Middle Aged

KW - Receptors, Virus

M3 - SCORING: Journal article

C2 - 22399632

VL - 32

SP - 1057

EP - 1062

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 3

ER -